NCT06078137

Impact of an Enhanced Patient Reported Outcome Measurement (PROM) Strategy on PROM Completion Rates

Active, enrolled NA Last updated 31 July 2025

What this trial tests

NA trial testing Usual PROMs and new PROMs strategy in PROM in 200 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 September 2023

Primary endpoint
1 January 2025

1 December 2025

Quick facts

Lead sponsor	University of Texas at Austin
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	single
Primary purpose	basic science
Enrollment	200
Start date	1 September 2023
Primary completion	1 January 2025
Estimated completion	1 December 2025
Sites	1 location across United States

Drugs / interventions tested

• Usual PROMs and new PROMs strategy

Conditions studied

• PROM — all drugs for PROM →

Sponsor

University of Texas at Austin

Who can join

Adults 18 to 89, any sex, with PROM. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

in clinical practice has been curbed by issues related to the variability in use of these tools for decision-making, and universally poor completion rates over time. Patients may not see the relevance of responding to questions about their health, and the results may not be reviewed by the clinician or presented and visualized with the patient. The questions may seem impersonal (e.g. too general and not directly assessing their individual goals, motivations, aspirations), irrelevant (e.g., asking about symptoms of depression when a person is seeking musculoskeletal specialty care) and insensitive (e.g., asking about sensitive subjects at the outset thereby disengaging the individual), and redundant or awkward (e.g., presenting questions that seem very similar or administered in strange orders). Finally, PROMs may also confer some burden (e.g., long PROM questionnaires often used for research may be unnecessarily burdensome for patient care), and provide logistical challenges (e.g., difficulties in administering the tools at the right time points), adding to a poor patient experience.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.